Table 4.
Comparison of clinical features between HRV‐positive and HRV‐negative outpatients with asthma exacerbations
| HRV N (%) | HRV‐positive N (%) | |||||
|---|---|---|---|---|---|---|
| Variable | Positive (n = 14) | Negative (n = 74) | P | HRV‐A (n = 3) | HRV‐C (n = 9) | P |
| Male:female | 8:6 | 49:25 | 0.729 | 2:1 | 5:4 | 1.000 |
| Age (median, month) | 60 | 64 | 0.941 | 54 | 56 | 0.926 |
| History of allergic rhinitis | 12 (85.7) | 49 (66.2) | 0.257 | 1 (33.3) | 9 (100) | 0.045 |
| History of eczema | 5 (35.7) | 24 (32.4) | 1.000 | 1 (33.3) | 4 (44.4) | 1.000 |
| Familial allergic rhinitis | 3 (21.4) | 10 (13.5) | 0.723 | 1 (33.3) | 2 (22.2) | 1.000 |
| Familial eczema | 3 (21.4) | 3 (4.1) | 0.049 | 1 (33.3) | 2 (22.2) | 1.000 |
| Familial asthma | 1 (7.1) | 12 (16.2) | 0.641 | 0 (0) | 1 (11.1) | 1.000 |
| Passive smoking | 6 (42.9) | 18 (24.3) | 0.271 | 0 (0) | 5 (55.6) | 0.310 |
| Cough | 13 (92.9) | 71 (95.9) | 0.507 | 3 (100) | 8 (88.9) | 1.000 |
| Expectoration | 6 (42.9) | 22 (29.7) | 0.513 | 2 (66.7) | 3 (33.3) | 0.735 |
| Wheezing | 13 (92.9) | 57 (77.0) | 0.324 | 3 (100) | 8 (88.9) | 1.000 |
| Fever | 1 (7.1) | 1 (1.4) | 0.294 | 0 (0) | 1 (11.1) | 1.000 |
| Tachypnea | 6 (42.9) | 14 (18.9) | 0.107 | 0 (0) | 5 (55.6) | 0.310 |
| White blood cell (×109/L) | 10.22 ± 3.66 | 9.85 ± 3.06 | 0.698 | 9.49 ± 2.76 | 11.26 ± 3.47 | 0.307 |
| Neutrophils (%) | 56.87 ± 13.93 | 46.95 ± 12.63 | 0.030 | 60.67 ± 17.21 | 58.43 ± 11.39 | 0.540 |
| Eosinophils (%) | 6.26 ± 3.68 | 6.48 ± 3.94 | 0.791 | 8.33 ± 6.81 | 5.39 ± 2.30 | 0.757 |
| FEV1% predicted | 91.68 ± 12.78 | 92.69 ± 14.12 | 0.913 | 92.70 ± 0 | 95.30 ± 12.89 | 0.655 |
| PEF% predicted | 93.35 ± 11.39 | 80.25 ± 19.47 | 0.147 | 75.30 ± 0 | 96.20 ± 12.08 | 0.180 |
| Positive skin tests | 7 (50.0) | 42 (58.1) | 0.431 | 1 (33.3) | 6 (66.7) | 0.735 |
FEV1, forced expiratory volume in one second; PEF, peak expiratory flow. Two‐sided P‐values of < 0.05were considered statistically significant.